The use of dendritic cells in cancer immunotherapy (Q35084257)

6 August 2017

1 reference

title

The use of dendritic cells in cancer immunotherapy. (English)

1 reference

6 August 2017

1 reference

1 reference

3

Ralph M Steinman

1 reference

6 August 2017

Beatrice Schuler-Thurner

series ordinal

2

object named as

Beatrice Schuler-Thurner

1 reference

6 August 2017

Gerold Schuler

1

1 reference

6 August 2017

publication date

1 April 2003

1 reference

Current Opinion in Immunology

6 August 2017

published in

1 reference

6 August 2017

volume

15

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

138-147

1 reference

The dendritic cell and human cancer vaccines

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Dendritic cells as vectors for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Active immunization against cancer with dendritic cells: the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Differentiation of T regulatory cells by immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Immune tolerance after delivery of dying cells to dendritic cells in situ

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Mouse and human dendritic cell subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Large-scale culture and selective maturation of human Langerhans cells from granulocyte colony-stimulating factor-mobilized CD34+ progenitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Cross-presentation of HLA class I epitopes from exogenous NY-ESO-1 polypeptides by nonprofessional APCs

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Immune complex-mediated antigen presentation induces tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Immunology. Licence to kill

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Dendritic cells injected via different routes induce immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

CD8+ T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Misconduct trouble brewing in Göttingen.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Tracking T cells with tetramers: new tales from new tools

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Functional heterogeneity of vaccine-induced CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Exosomes: composition, biogenesis and function

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2803%2900015-3

7 January 2021

10.1016/S0952-7915(03)00015-3

Identifiers

DOI

1 reference

6 August 2017

1 reference